REGENXBIO Inc. announced that Curran Simpson, Chief Operating Officer, has been appointed as Chief Executive Officer, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as Chief Executive Officer following 15 years of leadership at the Company, effective July 1, 2024. Mr. Simpson is a seasoned biopharmaceuticals leader with over 35 years of industry experience.

As the Chief Operating Officer (COO) at REGENXBIO since January 2023, he has been directly responsible for key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson, aged 62, joined REGENXBIO in 2015 and served as the Company?s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK).

Mr. Simpson earlier served as interim CEO at Human Genome Sciences (HGS), where he led the integration of HGS into GSK. Mr. Simpson has served as the Chief Operating Officer at REGENXBIO since January 2023. In that role, he has been leading key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations.

Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company?s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS.

Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin® and Avastin®, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemical engineering and chemistry from the Clarkson College of Technology.